H&E

H&E Equipment Services, Inc. Announces Participation in the Wells Fargo Industrials Conference

Retrieved on: 
Thursday, April 28, 2022
Automotive, Other Automotive, Other Construction & Property, Commercial Building & Real Estate, Construction & Property, Fleet Management, EST, NASDAQ, H&E, Conference, Investor relations, Pacific Northwest, Oil, Intermountain

H&E Equipment Services, Inc. (NASDAQ: HEES) today announced that Brad Barber, Chief Executive Officer, will participate in a fire-side chat during the Wells Fargo Industrials Conference on Wednesday, May 4, 2022.

Key Points: 
  • H&E Equipment Services, Inc. (NASDAQ: HEES) today announced that Brad Barber, Chief Executive Officer, will participate in a fire-side chat during the Wells Fargo Industrials Conference on Wednesday, May 4, 2022.
  • The fire-side chat is scheduled to begin at 9:20 AM, EST and is accessible through a link posted on the Companys website, www.he-equipment.com , under the Investor Relations tab in Events and Presentations.
  • Founded in 1961, H&E Equipment Services, Inc. is one of the largest rental equipment companies in the nation.
  • The Companys fleet is among the industrys youngest and most versatile with a superior equipment mix comprised of aerial work platforms, earthmoving, material handling, and other general and specialty lines.

H&E Equipment Services, Inc. Reports First Quarter 2022 Results

Retrieved on: 
Wednesday, April 27, 2022
Fleet Management, Other Construction & Property, Other Automotive, Automotive, Construction & Property, H&E, Projection, Public expenditure, GAAP, OEC, Pacific Northwest, Disease, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Risk, Natural gas, NASDAQ, Adobe Acrobat, Lists of disasters, Total, Annual report, Compliance, EBITDA, SG, Uncertainty, Growth, Company, Eastern Time Zone, Maintenance, Forward-looking statement, Income, Â, Industry, Acquisition, Renting, Television, Video game, Renewable energy, Intermountain

Used equipment sales decreased 44.6% in the first quarter of 2022 to $21.5 million compared to $38.9 million in the same quarter of 2021.

Key Points: 
  • Used equipment sales decreased 44.6% in the first quarter of 2022 to $21.5 million compared to $38.9 million in the same quarter of 2021.
  • Gross margin improved to 41.0% in the first quarter of 2022 compared to 34.7% in the first quarter of 2021.
  • Total equipment rental gross margins were 44.9% in the first quarter of 2022 compared to 38.0% in the same quarter of 2021.
  • Average time utilization (based on original equipment cost) in the first quarter of 2022 was 70.4% compared to 64.1% in the first quarter of 2021.

H&E Equipment Services Announces 2022 First Quarter Earnings and Conference Call Date

Retrieved on: 
Wednesday, April 20, 2022
NASDAQ, Adobe Acrobat, H&E, Eastern, Company, Eastern Time Zone, BATON, GLOBE, Pacific Northwest, Oil, Intermountain

BATON ROUGE, La., April 20, 2022 (GLOBE NEWSWIRE) -- H&E Equipment Services, Inc. (NASDAQ: HEES) today announced that it will release its 2022 first quarter financial results before the market on Wednesday, April 27, 2022.

Key Points: 
  • BATON ROUGE, La., April 20, 2022 (GLOBE NEWSWIRE) -- H&E Equipment Services, Inc. (NASDAQ: HEES) today announced that it will release its 2022 first quarter financial results before the market on Wednesday, April 27, 2022.
  • The Company will also hold a conference call to discuss first quarter results on Wednesday, April 27, 2022, at 10:00a.m.
  • The live broadcast of H&E Equipment Services quarterly conference call will be available online at www.he-equipment.com on April 27, 2022, beginning at 10:00 a.m. (Eastern Time) and will continue to be available for 30 days.
  • Founded in 1961, H&E Equipment Services, Inc. is one of the largest rental equipment companies in the nation.

Deep Bio Presents Research Results of AI-based Cancer Diagnosis and Prognosis at the AACR Annual Meeting 2022

Retrieved on: 
Monday, April 11, 2022
Risk, Adenocarcinoma, Medicine, Diagnosis, Medical device, IVD, Prostate, Stanford University School of Medicine, Survival, AACR, Research, Malignancy, Pathology, American Association, Workload, MFDS, Cancer, CEO, CTO, Marie Cassidy, 2021 Essex County Council election, Association, American Association for Cancer Research, Survival analysis, H&E, Prostate cancer, WSI, Ministry, VisionAire 500K, Breast cancer, AI, Deep learning, Patient, Prognosis, Algorithm, Medical imaging, Food

SEOUL, South Korea, April 11, 2022 /PRNewswire-PRWeb/ -- Deep Bio, a pioneer in medical AI for pathologic cancer diagnostics, presented five abstracts in regards to cancer diagnosis and prognosis of multiple cancer types using deep learning-based algorithms at the American Association for Cancer Research (AACR) 2022 which took place both in-person and virtually in New Orleans.

Key Points: 
  • SEOUL, South Korea, April 11, 2022 /PRNewswire-PRWeb/ -- Deep Bio, a pioneer in medical AI for pathologic cancer diagnostics, presented five abstracts in regards to cancer diagnosis and prognosis of multiple cancer types using deep learning-based algorithms at the American Association for Cancer Research (AACR) 2022 which took place both in-person and virtually in New Orleans.
  • Deep Bio also shared meaningful study results in prostate cancer, its core research area.
  • Tae-Yeong Kwak, the CTO of Deep Bio, said, "Prognosis analysis of cancer is crucial in that it directly affects patients' treatment and care plans.
  • "By presenting significant research results at this year's AACR, Deep Bio not only showcased its commitment to AI-based cancer diagnosis and digital pathology but also expanded its presence globally.

Histolix Digital FIBI Equivalency Study Results in No Major Discordance to Conventional FFPE Pathology Standards

Retrieved on: 
Tuesday, April 5, 2022
Adoption, Medicine, University, University of California Television, Eosin, DNA, Diagnosis, Biopsy, Transport, Microscopy, Pathology, ROSE, CEO, RNA, Marie Cassidy, MD, Health, Haematoxylin, Technology, DP, H&E, Goal, Workflow, UC, Archives of Pathology & Laboratory Medicine, WSI, Formaldehyde, Leica, FDA, University of California, Davis, AI, Digital pathology, Medical imaging, Pharmaceutical industry

DAVIS, Calif., April 5, 2022 /PRNewswire-PRWeb/ -- Histolix, a leading developer of direct-to-digital read pathology solutions, recently published the results of its Fluorescence Imitating Brightfield Imaging (FIBI) equivalency study to the standard Formalin-fixed and Paraffin-embedded (FFPE) conventional pathology methodology. The study showed no major discordance between the two methodologies, which could enable significant time savings in providing rapid and accurate pathological analysis. This breakthrough advance could reduce such analysis time from the current eight hours or more for completion to under 10 minutes.

Key Points: 
  • DAVIS, Calif., April 5, 2022 /PRNewswire-PRWeb/ -- Histolix, a leading developer of direct-to-digital read pathology solutions, recently published the results of its Fluorescence Imitating Brightfield Imaging (FIBI) equivalency study to the standard Formalin-fixed and Paraffin-embedded (FFPE) conventional pathology methodology.
  • The study showed no major discordance between the two methodologies, which could enable significant time savings in providing rapid and accurate pathological analysis.
  • The Histolix study uses the same study design," said Alexander Borowsky, MD, professor of Pathology and Medicine at UC Davis and chief medical officer for Histolix.
  • In coordination with the founding team, Histolix is recently concluded a 100-tissue sample equivalency validation study across multiple tissue types, resulting in no major discordance with conventional FFPE pathology standards.

Deep Bio Presented Deep Learning-based Cancer Research at the USCAP 111th Annual Meeting

Retrieved on: 
Wednesday, March 23, 2022
Medicine, Diagnosis, Medical device, IVD, Prostate, Breast, Research, Pathology, Prognosis, Workload, MFDS, Cancer, CEO, CTO, Marie Cassidy, USCAP, United States and Canadian Academy of Pathology, Survival analysis, H&E, Prostate cancer, Breast cancer, Deep learning, Ministry, VisionAire 500K, Stanford University School of Medicine, Medical imaging, Food

The studies explore how deep learning can be utilized in cancer diagnosis, prognosis, and prediction of multiple cancer types, including prostate, breast, lungs, etc.

Key Points: 
  • The studies explore how deep learning can be utilized in cancer diagnosis, prognosis, and prediction of multiple cancer types, including prostate, breast, lungs, etc.
  • In particular, novel research studies such as "Deep Learning-based Automated Detection of Prostate Cancer Lesions in Hematoxylin Only Visualized Images" and "Breast Cancer Survival Analysis through the Extracted Feature from the Prostate Diagnosis Model" drew attention from the USCAP attendees.
  • About Deep Bio Deep Bio Inc. is an AI biotech company with in-house expertise in deep learning, pathology, life sciences, and pharmacotherapeutics.
  • Deep Bio is actively engaged in the research space and participating in ongoing collaborations with top US medical centers.

Tempus’ EDGE Platform Leverages Data & AI to Identify Therapeutic Options for Patients Earlier in the Treatment Journey

Retrieved on: 
Monday, March 21, 2022
Software, Research, Pharmaceutical, Oncology, Data Management, Technology, Genetics, Clinical Trials, Science, Biotechnology, Other Technology, Health, MSI, Biomarker, GM, Therapy, Janssen, Microsatellite instability, Library, EDGE, HRD, Pathology, Precision medicine, CEO, Intelligence, Marie Cassidy, Translation, AstraZeneca, SVP, Data science, MD, Health, H&E, Physician, Development, Oncology, Patient, NAPA, Algorithm, Medical device, Medical imaging, Pharmaceutical industry, Tempus

With access to over 50 petabytes of de-identified multimodal data, Tempus is developing AI models with the aim to identify patients who would benefit from additional testing and may qualify for targeted therapies, including those in clinical trials, earlier in their cancer care journey.

Key Points: 
  • With access to over 50 petabytes of de-identified multimodal data, Tempus is developing AI models with the aim to identify patients who would benefit from additional testing and may qualify for targeted therapies, including those in clinical trials, earlier in their cancer care journey.
  • Tempus is creating a network of pathology labs, called NAPA, across the country that can access the companys growing portfolio of investigational AI models designed to identify patients that are more likely to have targetable biomarkers.
  • In addition, Tempus is collaborating with some of the worlds leading pharmaceutical and biotech companies to leverage the EDGE platform and NAPA network to identify unique biomarkers and co-develop novel AI applications.
  • Tempus also announced a strategic collaboration with AstraZeneca last year, which intends to utilize Tempus AI-enabled platform and multimodal data to advance novel therapeutic programs across AstraZenecas diverse oncology pipeline.

Lunit AI Demonstrates Accuracy in Practical Assessment of Cancer Tissue-Findings to Be Presented at USCAP 2022

Retrieved on: 
Sunday, March 20, 2022
Method, Biomarker, Large-cell lung carcinoma, Immunotherapy, Multimedia, NGS, Progression-free survival, Cancer, Decision-making, CEO, NSCLC, Marie Cassidy, 2021 Essex County Council election, USCAP, View, Bias, United States and Canadian Academy of Pathology, H&E, Annual general meeting, TPS, WSI, AI, PD-L1, Patient, Prognosis, Medical device, Medical imaging

As a leading medical AI provider, Lunit focuses on developing novel AI biomarkers for application in cancer treatment.

Key Points: 
  • As a leading medical AI provider, Lunit focuses on developing novel AI biomarkers for application in cancer treatment.
  • Since 2019, the company has presented groundbreaking findings using its AI-powered tissue analysis platform, 'Lunit SCOPE.'
  • Through digital analysis of histopathological whole slide images (WSI), the studies have validated the predictive value of Lunit SCOPE in immunotherapy.
  • One of the USCAP abstracts showcases Lunit's AI-powered tumor purity (AI-P) assessment method using the company's AI biomarker platform, Lunit SCOPE IOpart of the Lunit SCOPE product line.

Ultivue Announces Co-Marketing Agreement with Aignostics for Unique Spatial AI-Powered Imaging Solutions for Translational Medicine

Retrieved on: 
Wednesday, March 9, 2022
Software, Research, General Health, Pharmaceutical, Oncology, Data Management, Technology, Genetics, Science, Biotechnology, Other Science, Health, Industry, Clinical trial, Pathology, Partnership, Research, Workflow, Artificial intelligence, Precision medicine, IHC, H&E, GCP, Solution, Technology, Cdx, MIF, CEO, Algorithm, NSCLC, Medical imaging, Pharmaceutical industry, Sutro Biopharma, Technical University of Berlin, Ultivue, Aignostics, ULTIVUE, AIGNOSTICS

These results will be published later this year and respective AI models made available via the platform.

Key Points: 
  • These results will be published later this year and respective AI models made available via the platform.
  • We are excited to start offering this approach to our clients for translational science and clinical trials, said Viktor Matyas, CEO of Aignostics.
  • Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.
  • These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.

Paige and Mindpeak Announce Partnership to Expand Access to Industry-Leading AI Software for Breast Cancer

Retrieved on: 
Tuesday, February 15, 2022
General Health, Health, Data Management, Technology, Software, Memorial Sloan Kettering Cancer Center, MSK, Adoption, Patient, AI, CEO, Biomarker, Health, Research, HER2, Technology, LIS, Breast cancer, Artificial intelligence, FDA, Marie Cassidy, Partnership, H&E, Pathology, Workflow, IHC, Diagnosis, Â, Oncology, Medical imaging, Medical device, EU

Mindpeaks BreastIHC is an AI software that reliably and accurately detects, classifies and quantifies breast cancer cells.

Key Points: 
  • Mindpeaks BreastIHC is an AI software that reliably and accurately detects, classifies and quantifies breast cancer cells.
  • This partnership enhances the utility of the Paige Platform by providing real-time results for routine breast cancer immunohistochemistry (IHC) biomarkers.
  • The detection and quantification of IHC markers is an important step in treatment planning for breast cancer.
  • By combining MindPeaks products for IHC with Paiges AI products for H&E, our partnership will allow pathologists to drive efficient routine clinical cancer diagnostics in breast cancer, said Andy Moye, Ph.D., Chief Executive Officer at Paige.